

# Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

NCT06490081

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
<b>Enrollment</b>	40 participants

## Plain Language Summary

---

This study is testing whether a drug called trilaciclib can reduce bone marrow suppression (low blood cell counts) caused by chemoradiotherapy in people with limited-stage small cell lung cancer. Trilaciclib temporarily protects bone marrow cells from chemotherapy damage.

**\*\*You may be eligible if...\*\***

- You have limited-stage small cell lung cancer (cancer confined to one side of the chest)
- Your overall health is adequate for combined chemotherapy and radiation (ECOG 0–2)
- Your organ function is in acceptable range

**\*\*You may NOT be eligible if...\*\***

- You have brain metastases that require radiation or steroids
- You have an active infection requiring systemic treatment
- You are pregnant or breastfeeding
- You have certain heart conditions or significant autoimmune diseases

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (5)

- The histopathology is limited-stage small cell lung cancer.
- ECOG score 0-2.
- Good organ function (no blood transfusions, no hematopoietic stimulating factors, no transfusions of albumin or blood products within 14 days prior to the examination).
- It is suitable for patients treated with Trilaciclib combined with etoposide plus cisplatin or carboplatin.
- Understand and can sign informed consent

### Exclusion (5)

- Brain metastases with clinical symptoms require local radiotherapy or hormone therapy.
- Active infections require systemic treatment.
- Subjects with active, known or suspected autoimmune disease or history of autoimmune disease.
- Combined with other tumors.
- The current or previous presence of a clinically significant and medically unstable condition, which in the investigator's professional judgment may compromise subject safety, interfere with study evaluation or endpoint assessment, or otherwise impact the reliability of study results.

## Locations (1 total)

---

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China

---

<https://clinicaltrials.gov/study/NCT06490081>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).